WEF25: Saudi Foreign Minister Says Middle East Has “Opportunity to Turn a Page” Following Gaza Ceasefire
22.1.2025 13:25:00 CET | Business Wire | Press release
Saudi Arabia’s Minister of Foreign Affairs, His Highness Prince Faisal bin Farhan bin Abdullah, today said the Middle East has an opportunity to shape a prosperous future following the Gaza ceasefire deal which came into effect at the start of the week.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250121797711/en/
Saudi Arabia’s Minister of Foreign Affairs, His Highness Prince Faisal bin Farhan bin Abdullah, addressed a panel session at the World Economic Forum Annual Meeting 2025 in Davos on ‘Diplomacy amid Disorder’, where he spoke about an opportunity for the region “to turn a page” (Photo: AETOSWire)
“We are certainly in a region that is abundant with risk factors. But we are also in a region that has huge potential. Even with a very difficult year behind us, we have shown we can be resilient as a region and we can look to the future, whether it’s the Kingdom, the GCC countries and their ability to stay on track with their economic agendas. But also, as we see now with Syria, Lebanon, and possibly now in Gaza – there is positivity there.
“The opportunity to turn a page exists in the whole region. I choose to be optimistic,” the Saudi Minister of Foreign Affairs said.
His Excellency Ahmed A. Al-Khateeb, Minister of Tourism, in a session titled ‘Travel and Tourism’s Role in Building Trust,’ commented: “Since opening our doors back in 2019, we’ve been blessed to receive millions of international arrivals. We started with 10 million tourists in 2019, and last year hit almost 30 million. Travel and tourism is contributing to building a diversified and more resilient economy.”
During a Saudi House panel session on ‘New Approaches to Measuring Growth Beyond GDP’, His Excellency Mohammed A. Aljadaan, Minister of Finance, emphasized that growth should not be limited to GDP alone. He highlighted the importance of monitoring additional indicators to ensure that growth is both inclusive and sustainable across various dimensions.
Speaking in a panel on ‘The Future of Growth’, His Excellency Faisal F. Alibrahim, Minister of Economy and Planning, highlighted the Kingdom’s long-term approach to growth: “Saudi Vision 2030 is an example of bold leadership that has led us to plan with confidence, deliver with optimism, but also manage with prudence.”
The WEF released a briefing paper with expert input from HE Al-Khateeb, Minister of Tourism, on ‘The Future of Travel and Tourism: Embracing Sustainable and Inclusive Growth’ exploring trends in the sector and the importance of cross-sector collaboration. The Ministry of Tourism also released an Investor White Paper highlighting initiatives transforming the Kingdom's tourism sector under Vision 2030.
During a Saudi House session hosted by the Ministry of Investment and Ministry of Communications and Information Technology, Salesforce announced plans to open a new regional headquarters in Riyadh, pledging to provide upskilling opportunities to 30,000 Saudi citizens by 2030. The firm also announced a partnership agreement with IBM to open an AI Innovation Center in the Kingdom.
Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20250121797711/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom